Anna Becker
Clinical Psychopharmacologist and Clinical Researcher
Papers
Trials
Key Impact
Notable for leading early-phase, placebo-controlled human trials that characterise the acute effects, safety and pharmacokinetics of classic and novel psychedelics and for investigating interactions with serotonergic antidepressants.
Background & Research
Anna Becker is a clinical psychopharmacologist whose recent work has focused on rigorous, experimental human pharmacology studies of classic and novel psychedelics. She has been a key investigator on multiple randomized, double-blind, placebo-controlled, cross-over Phase I studies in healthy volunteers that examine acute subjective and physiological effects, safety profiles and pharmacokinetics of compounds including psilocybin, LSD, mescaline, intravenous DMT and MDMA–LSD co-administration. Becker’s research frequently addresses clinically important questions such as the influence of selective serotonin reuptake inhibitors on psychedelic response and the comparative acute profiles of different serotonergic hallucinogens.